Human circulating and tissue-resident memory CD8+ T cells
Our current knowledge of human memory CD8+ T cells is derived largely from studies of the
intravascular space. However, emerging data are starting to challenge some of the dogmas …
intravascular space. However, emerging data are starting to challenge some of the dogmas …
HBV/HIV coinfection: impact on the development and clinical treatment of liver diseases
Z Cheng, P Lin, N Cheng - Frontiers in medicine, 2021 - frontiersin.org
Hepatitis B virus (HBV) infection is a common contributor to chronic hepatitis, liver cirrhosis,
and hepatocellular carcinoma. Approximately 10% of people with human immunodeficiency …
and hepatocellular carcinoma. Approximately 10% of people with human immunodeficiency …
Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study
Importance Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand
(PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable …
(PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable …
Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV
JM Benito, C Restrepo, J García-Foncillas… - Frontiers in …, 2023 - frontiersin.org
The immune system of people living with HIV (PLWH) is persistently exposed to antigens
leading to systemic inflammation despite combination antiretroviral treatment (cART). This …
leading to systemic inflammation despite combination antiretroviral treatment (cART). This …
Opportunities for CAR-T cell immunotherapy in HIV cure
G Campos-Gonzalez, J Martinez-Picado… - Viruses, 2023 - mdpi.com
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood
malignancy field and is becoming a well-established therapy for many types of leukaemia. In …
malignancy field and is becoming a well-established therapy for many types of leukaemia. In …
Chronic inflammation mediates brain injury in HIV infection: relevance for cure strategies
JC McArthur, TP Johnson - Current opinion in neurology, 2020 - journals.lww.com
As therapies are developed to cure HIV, it is important to protect the CNS from additional
immune-mediated damage. Adjunctive therapies to restore glial function, reduce …
immune-mediated damage. Adjunctive therapies to restore glial function, reduce …
Immune checkpoint inhibitors in infectious disease
HAD King, SR Lewin - Immunological Reviews, 2024 - Wiley Online Library
Following success in cancer immunotherapy, immune checkpoint blockade is emerging as
an exciting potential treatment for some infectious diseases, specifically two chronic viral …
an exciting potential treatment for some infectious diseases, specifically two chronic viral …
Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART
O Blanch-Lombarte, D Ouchi, E Jimenez-Moyano… - Elife, 2023 - elifesciences.org
The co-expression of inhibitory receptors (IRs) is a hallmark of CD8+ T-cell exhaustion (Tex)
in people living with HIV-1 (PLWH). Understanding alterations of IRs expression in PLWH on …
in people living with HIV-1 (PLWH). Understanding alterations of IRs expression in PLWH on …
[HTML][HTML] Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
M Gonzalez-Cao, T Puertolas, M Riveiro… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint
inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown …
inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown …
[HTML][HTML] Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
Background The Food and Drug Administration recommends that people living with HIV
(PWH) with a CD4+ T cell count (CD4)≥ 350 cells/µL may be eligible for any cancer clinical …
(PWH) with a CD4+ T cell count (CD4)≥ 350 cells/µL may be eligible for any cancer clinical …